Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.19.1
Consolidated Statements of Comprehensive Loss
₪ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
ILS (₪)
₪ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Dec. 31, 2017
ILS (₪)
₪ / shares
shares
Dec. 31, 2016
ILS (₪)
₪ / shares
shares
Profit (loss) [Abstract]        
Revenue ₪ 18,034 $ 4,812 ₪ 1,668 ₪ 292
Cost of revenue 1,426 380 52
Gross profit 16,608 4,432 1,616 292
Research and development expenses:        
Research and development expenses 16,213 4,325 16,921 29,200
Participation in research and development expenses, net 3,227 861 (2,855) (12,411)
Research and development expenses, net 19,440 5,186 14,066 16,789
General, administrative and marketing expenses 12,480 3,330 8,303 11,048
Operating loss (15,312) (4,084) (20,753) (27,545)
Financial income 1,650 440 253 93
Financial expenses (225) (60) (380) (441)
Financial income (expenses), net 1,425 380 (127) (348)
Comprehensive loss ₪ (13,887) $ (3,704) ₪ (20,880) ₪ (27,893)
Basic and diluted loss per ordinary share (NIS/USD) | (per share) ₪ 0.06 $ 0.02 ₪ 0.16 ₪ 0.28
Weighted average ordinary shares outstanding 219,229,229 219,229,229 133,187,048 100,624,945